Diagonal Bio Past Earnings Performance
Past criteria checks 0/6
Diagonal Bio's earnings have been declining at an average annual rate of -19.1%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 42.9% per year.
Key information
-19.1%
Earnings growth rate
26.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -42.9% |
| Return on equity | -60.1% |
| Net Margin | -462.9% |
| Next Earnings Update | 22 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Diagonal Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2 | -11 | 13 | 0 |
| 31 Dec 23 | 3 | -12 | 15 | 0 |
| 30 Sep 23 | 4 | -13 | 16 | 0 |
| 30 Jun 23 | 4 | -14 | 17 | 0 |
| 31 Mar 23 | 4 | -16 | 18 | 0 |
| 31 Dec 22 | 4 | -16 | 17 | 0 |
| 30 Sep 22 | 4 | -16 | 17 | 0 |
| 30 Jun 22 | 5 | -16 | 16 | 0 |
| 31 Mar 22 | 6 | -14 | 15 | 0 |
| 31 Dec 21 | 9 | -12 | 12 | 0 |
| 30 Sep 21 | 14 | -9 | 8 | 0 |
| 31 Dec 20 | 8 | -1 | 1 | 0 |
Quality Earnings: 9F1 is currently unprofitable.
Growing Profit Margin: 9F1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9F1 is unprofitable, and losses have increased over the past 5 years at a rate of 19.1% per year.
Accelerating Growth: Unable to compare 9F1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9F1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 9F1 has a negative Return on Equity (-60.11%), as it is currently unprofitable.